Poor
Mostly Aligned
Patient Risk:
Medium
Summary
Only limited elements align with the provided FDA label text (dizziness/somnolence warning and general dosing schedule structure). Most workout- and timing/frequency-change advice and several specific adverse-effect claims are unsupported by the supplied label sections, resulting in poor label alignment.
Category Scores
Accurate Statements
Pregabalin (Lyrica) can cause side effects that can affect balance, coordination, and reaction time.
Partially supported via label section on dizziness and somnolence (5.5), which may impair ability to perform tasks such as driving/operating machinery; however the claim expands into balance/coordination/reaction time explicitly.
Pregabalin has specific dosing schedules based on the condition being treated.
Partially supported: labeling includes condition-specific recommended dosage/frequency and dose changes based on response/tolerability (2.4).
Pregabalin commonly causes dizziness or lightheadedness.
Partially supported: label reports dizziness and somnolence in clinical trials (5.5); 'lightheadedness' is not explicitly stated.
Pregabalin commonly causes sleepiness or fatigue.
Partially supported: label reports somnolence (5.5); 'fatigue' is not explicitly stated in the provided section.
Pregabalin side effects that affect ability to perform tasks (e.g., driving/operating machinery) soon after dosing can be dangerous.
Partially supported: 5.5 states dizziness/somnolence may impair ability to perform tasks such as driving or operating machinery.
Unsupported Statements
Taking pregabalin solely before every workout is not something that should be assumed safe or appropriate.
No label support in the provided sections for workout-based timing/safety judgments.
Taking pregabalin more often or at different times than prescribed can increase the risk of side effects.
No label support in the provided sections for increased risk specifically from altering frequency/timing.
Pregabalin commonly causes blurred vision.
Blurred vision is not supported in the provided label excerpts.
Pregabalin commonly causes problems with coordination or balance.
No explicit label support for coordination problems or balance impairment (the provided label supports dizziness/somnolence).
Pregabalin side effects can raise the risk of falls, missteps, or slower reactions during lifting, running, cycling, or using equipment.
Falls/missteps and specific exercise activities are not supported in the provided sections.
Pregabalin side effects may be especially risky during high-intensity or technical workouts.
Workout-intensity/technical activity risk stratification is not supported in the provided sections.
If pregabalin is prescribed for a chronic condition such as neuropathic pain or seizures, the key question is whether the prescription timing already covers workouts.
No label support for addressing workout coverage or exercise-timing decisions.
For pregabalin prescribed for chronic conditions, the response advises following the prescriber’s schedule rather than adding extra doses or shifting doses to before every workout.
No label support for workout-based dose shifting decisions or the specific phrasing.
If symptoms flare during exercise, the response advises adjusting the overall dosing plan with a clinician rather than changing it independently around workouts.
No label support in the provided sections for exercise-related flare handling or workout-specific dosing changes.
Using pregabalin as a workout supplement for soreness or performance is a safety concern.
No label support for use as a workout supplement; provided sections do not address this use.
Pregabalin is not an approved sports performance medication.
No provided label section addresses sports performance approval status.
The response states that pregabalin has dependence and withdrawal risks.
Dependence/withdrawal is not supported by the provided label excerpts (9 is not included; only a reference to tapering is shown in 2.1 but dependence/withdrawal risk is not explicitly provided in the supplied text as a claim).
The response states pregabalin should only be used under medical direction for an approved indication.
No provided label excerpt supports this generalization.
Risk with pregabalin around workouts tends to rise if a person is new to pregabalin or has recently increased the dose.
No provided label support for workout-specific timing/risk by recency of dose initiation/escalation.
Risk with pregabalin around workouts tends to rise if a person drinks alcohol or takes other sedating medicines.
The provided excerpts include 5.5 and general 7 interaction principles without specific alcohol/sedating medicine guidance.
The combination of pregabalin with alcohol or other sedating medicines can worsen sleepiness or dizziness.
No provided label excerpt supports this specific combination claim.
The response states that exercise can be similar to driving in terms of coordination requirements.
No provided label excerpt compares exercise to driving/coordination requirements.
Risk with pregabalin around workouts tends to rise if a person has underlying balance issues, low blood pressure, or neurologic problems.
No provided label excerpt supports these specific risk modifiers.
If dizziness, unusual sleepiness, or coordination problems occur, the response advises avoiding workouts that require steady balance until the medication’s effects are known.
No provided label excerpt supports workout-avoidance instructions or 'steady balance' phrasing.
The response advises checking with a prescriber or pharmacist before taking a pregabalin dose more often or at a different time than prescribed.
No provided label excerpt includes this specific counseling instruction.
The response advises checking with a prescriber or pharmacist before starting a routine of taking pregabalin before every workout.
No provided label excerpt includes counseling about before-every-workout routines.
The response advises checking with a prescriber or pharmacist before taking pregabalin at a time it was not previously scheduled for.
No provided label excerpt includes this specific counseling instruction.
The response advises checking with a prescriber or pharmacist before changing pregabalin timing if experiencing side effects on exercise days.
No provided label excerpt supports this exercise-day-specific counseling.
Contradictions
Important Omissions
Contraindications and boxed warnings (if any) were not assessed against the provided label sections.
Importance:
High
Dependence/withdrawal warnings/precautions were not supported by the provided label excerpts, and the audit indicates potential missing label coverage.
Importance:
Moderate
Drug interaction details relevant to specific co-administration (e.g., sedating medicines/alcohol) were not supported by the provided label excerpts.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Several workout- and timing/frequency-change recommendations and specific risk modifiers (alcohol/sedating medicines, falls, blurred vision, dependence/withdrawal) are unsupported by the provided label excerpts. The only well-supported safety content is dizziness/somnolence affecting tasks like driving/operating machinery (5.5).
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most workout- and administration-timing counseling claims are absent from the provided label excerpts and should be removed or rephrased to match on-label wording (e.g., dizziness/somnolence impairing task performance; dosing frequency as prescribed).
Suggested Improvement
Constrain claims to provided label-supported content: dizziness/somnolence and potential impairment of driving/operating machinery (5.5), general dosing regimen structure and frequency/titration approach (2.4), and label-supported administration instructions (2.1). Remove workout-specific and alcohol/sedating-medicine combination claims unless supported by other label sections not provided.